Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion
Akero shareholders will receive $54 per share initially, plus $6 per share contingent on U.S. regulatory approval of its EFX drug by June 30, 2031.
In-Article-1
Desktop Banner (This ad will be displayed on screens larger than 992px)
Mobile Banner (This ad will be displayed on screens smaller than 992px)
In-Article-2 Desktop Banner (This ad will be displayed on screens larger than 992p
Mobile Banner (This ad will be displayed on screens smaller than 992px)
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
Carver
Carver who carves the news
